The FDA approved Merck’s Keytruda Qlex, a subcutaneously administered combination of pembrolizumab and berahyaluronidase alfa, becoming the first immune checkpoint inhibitor delivered under a minute. This administration route promises to streamline immunotherapy delivery for solid tumors, improving patient convenience and clinical workflow. The clearance follows prior approvals for SC formulations and marks a pivotal step in cancer treatment administration.